More Than a Weight Drug
While GLP-1 receptor agonists entered public awareness as weight-loss medications, their most consequential benefits may be cardiovascular and renal. Landmark trials have demonstrated that these drugs reduce major cardiovascular events — heart attacks, strokes, and cardiovascular death — in people with obesity and established heart disease, and slow the progression of chronic kidney disease. Critically, some of these benefits appear partly independent of weight loss, suggesting direct protective effects on the heart, blood vessels, and kidneys.
The Evidence Base
The SELECT trial showed that semaglutide reduced cardiovascular events in overweight and obese patients without diabetes but with existing heart disease, a finding that expanded the rationale for treatment beyond glycemic control and weight. Trials in kidney disease have shown reduced progression of renal decline. These results are reshaping guidelines, positioning GLP-1 drugs as cardiometabolic medications that address multiple linked conditions rather than isolated weight interventions.
Implications for Treatment
This expanding evidence means GLP-1 therapy may be appropriate for patients based on cardiovascular and kidney risk, not weight alone. It reframes obesity as one node in a network of metabolic disease and positions these medications as tools for comprehensive cardiometabolic protection. As access and evidence grow, integrating them into cardiology and nephrology care is becoming common. Facilities can source diagnostic equipment and patient care supplies from our catalog.
